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Abstract
In addition to the monographs which have been published
recently by the working group ‘‘Drug Monitoring’’ of the
Swiss Society of Clinical Chemistry (SSCC) w1, 2x, new
monographs have been written. The aim of these mono-
graphs is to provide an overview on the information which
is important for the request and interpretation of the
results. Therefore, the targeted readers are laboratory
health professionals and the receivers of the reports. In
this series, aminoglycoside as well as glycopeptide anti-
biotics are presented. In addition, two antimycotic drugs,
which are regularly quantified in sera of intensive care
patients, are described. Also, the monograph on meben-
dazole is shown. This drug is often used in high doses for
the treatment of infections with Echinococcus multilocu-
laris for which the measurement of drug concentrations in
serum is recommended. Information on the indication for
therapeutic drug monitoring (TDM), protein binding, met-
abolic pathways and enzymes involved, elimination half-
life and elimination routes, and therapeutic or toxic
concentrations is provided. Because pre-analytical con-
siderations are of particular importance for therapeutic
drug monitoring, there is also information given at which
time the determination of the drug concentration is
reasonable and when steady-state concentrations are
reached after changing the dose. Furthermore, the stability
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of the drug and its metabolite(s) after blood sampling is
described. For readers with a specific interest, references
to important publications are provided. The number of the
monographs will be continuously increased. The updated
files are presented on the homepage of the SSCC
(www.sscc.ch). We hope that these monographs are help-
ful for the better handling of therapeutic drug monitoring
and we are looking forward to comments by the readers.
Keywords: amikacin; gentamicin; itraconazole; meben-
dazole; netilmicin; teicoplanin; tobramycin; vancomycin;
voriconazole.
Zusammenfassung
In Erga¨nzung zu den in den letzten Jahren pub-
lizierten Arzneimittelmonographien der Arbeitsgruppe
Medikamente der Schweizerischen Gesellschaft fu¨r Kli-
nische Chemie (SGKC) w1, 2x, sind nun weitere Monogra-
phien erstellt worden. Ziel dieser Monographien ist es,
dem Labormediziner bzw. dem Empfa¨nger der Befunde
eine U¨bersicht u¨ber die wichtigsten Informationen zu
geben, die fu¨r die Veranlassung einer Analyse bzw. fu¨r
die Interpretation der Resultate hilfreich sind. In dieser
Serie werden die Aminoglykosid- und Glykopeptidanti-
biotika pra¨sentiert, wie auch zwei Antimykotika, bei
denen vor allem bei Intensivpatienten immer ha¨ufiger
Messungen im Serum durchgefu¨hrt werden. Zusa¨tzlich
wird die Monographie von Mebendazol pra¨sentiert, das
im Rahmen der Infektionen mit Echinococcus multilocu-
laris (Fuchsbandwurm) in hohen Dosen verabreicht und
im Serum bestimmt wird. In den einzelnen Monographien
werden klinisch pharmakologische Angaben wie zum
Beispiel Indikation fu¨r das Therapeutic Drug Monitoring
(TDM), Proteinbindungen, Metabolisierungswege und
daran beteiligte Enzyme, Halbwertszeiten und Elimina-
tionswege der Muttersubstanz, sowie Informationen zu
therapeutischen bzw. toxischen Bereichen, zur Verfu¨-
gung gestellt. Da die Pra¨analytik gerade beim Therapeu-
tic Drug Monitoring eine wichtige Rolle spielt werden
auch hier Angaben gemacht zu welchem Zeitpunkt eine
Bestimmung der Arzneimittelkonzentration sinnvoll ist
und wann, nach einer Dosisa¨nderung, der steady-state
erreicht ist. Außerdem werden Angaben u¨ber die Sta-
bilita¨t der Medikamente bzw. ihrer Metaboliten nach der
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Blutentnahme gemacht. Fu¨r die interessierten Leser sind
die verwendeten Referenzen als Zitate aufgefu¨hrt. Die
Zahl der Monographien wird fortlaufend erga¨nzt. Die
aktuellsten Versionen der Monographien sind auf der
Homepage der SGKC abrufbar (www.sscc.ch). Wir hof-
fen, dass diese Monographien im Umgang mit dem Ther-
apeutic Drug Monitoring hilfreich sein werden und freuen
uns u¨ber Kommentare und Bemerkungen.
Schlu¨sselwo¨rter: Amikacin; Gentamicin; Itraconazol;




• Class of the drug Aminoglycoside antibiotics
• Synonym(s) –
• Common trade name(s) in Germany Biklin
• Conversion factors mg/L=1.71smmol/L
mmol/L=0.58smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, suspicion of toxicity, side effects
• Protein binding 4–11% (albumin)
• Elimination half-life 1–4 h
Neonates/infants: 3–8 h (see remarks)
• Volume of distribution 0.3–0.4 L/kg
• Metabolism
Main metabolic pathways No metabolism
Active metabolite(s)? None
Inhibitor or inducer of the cytochrome P450 system? No
Other significant pharmacokinetic interactions None
• Elimination of parent drug Renal 100%
• Typical therapeutic range Multiple dosing
Peak concentration: 20–30 mg/L (34–51 mmol/L)
Trough concentration: F7 mg/L (F12 mmol/L)
Once-daily dosing
Trough concentration: F1.5 mg/L (F2.6 mmol/L)
• Potentially toxic concentration Multiple dosing
Peak concentration: )35 mg/L ()60 mmol/L)
Trough concentration: )10 mg/L ()17 mmol/L)
Once-daily dosing
Trough concentration: )1.5 mg/L ()2.6 mmol/L)
Pre-analytics
• Time to steady-state since beginning of treatment Steady-state is generally achieved after 3 doses for multiple
or change of posology dosing
• Time for blood sampling Peak: 1 h after beginning of infusion
Trough: within 30 min of next dose
Once-daily dosing: trough level only
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
When combined therapy with penicillins and/or
cephalosporins: in vitro inactivation™freeze sample
Remarks • Elimination is strongly dependent on renal function
• Avoid gel tubes if possible, unless having confirmed that no
binding occurs
References • Arzneimittelkompendium Schweiz. Basel: Documed 2005
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie
(16. Auflage). Basel: Documed, 2005
• Taylor WJ, Diers Caviness MH. A textbook for the clinical
application of therapeutic drug monitoring. Irving,
TX: Abbott Laboratories, 1986
• Thomson Micromedex Healthcare series
• Begg EJ, Barclay ML. Aminoglycosides – 50 years on. Br J
Clin Pharm 1995;39:597–603
• Schulz M, Schmoldt A. Therapeutic and toxic blood
concentrations of more than 800 drugs and other
xenobiotics. Pharmazie 2003;58:447–74
• Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness
of therapeutic drug monitoring committee of the international
association for therapeutic drug monitoring and clinical
toxicology. Ther Drug Monit 2005;27:10–7
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Gentamicin
General
• Class of the drug Aminoglycoside antibiotics
• Synonym(s) –
• Common trade name(s) in Germany Refobacin
• Conversion factors mg/L=2.1smmol/L (mean)
mmol/L=0.48smg/L (mean)
Clinical pharmacology
• Indications for TDM Individual dose adaptation, suspicion of toxicity, side effects
• Protein binding 0–30% (albumin)
• Elimination half-life 1–3 h
Neonates/infants: 3–8 h (see remarks)
• Volume of distribution 0.3 L/kg
• Metabolism
Main metabolic pathways No metabolism
Active metabolite(s)? None
Inhibitor or inducer of the cytochrome P450 system? No
Other significant pharmacokinetic interactions None
• Elimination of parent drug Renal 100%
• Typical therapeutic range Multiple dosing
Peak concentration: 6–10 mg/L (13–21 mmol/L)
Trough concentration: F1 mg/L (F2.1 mmol/L)
Once-daily dosing
Trough concentration: F0.5 mg/L (F1.1 mmol/L)
• Potentially toxic concentration Multiple dosing
Peak concentration: )12 mg/L ()25 mmol/L)
Trough concentration: )2 mg/L ()4 mmol/L)
Once-daily dosing
Trough concentration: )0.5 mg/L ()1.1 mmol/L)
Pre-analytics
• Time to steady-state since beginning of treatment Steady-state is generally achieved after 3 doses for multiple
or change of posology dosing
• Time for blood sampling Peak: 1 h after beginning of infusion
Trough: within 30 min of next dose
Once-daily dosing: trough level only
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
When combined therapy with penicillins and/or
cephalosporins: in vitro inactivation™freeze sample
Remarks • Elimination is strongly dependent on renal function
• Avoid gel tubes if possible, unless having confirmed that no
binding occurs
References • Arzneimittelkompendium Schweiz. Basel: Documed 2005
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie
(16. Auflage). Basel: Documed, 2005
• Taylor WJ, Diers Caviness MH. A textbook for the clinical
application of therapeutic drug monitoring. Irving,
TX: Abbott Laboratories, 1986
• Thomson Micromedex Healthcare series
• Begg EJ, Barclay ML, Duffull SB. A suggested approach to
once-daily aminoglycoside dosing. Br J Clin Pharm
1995;39:605–9
• Modi N, Maggs AF, Clarke C, Chapman C, Swann RA.
Gentamicin concentration and toxicity. Lancet 1998;352:70
• Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness
of therapeutic drug monitoring committee of the
international association for therapeutic drug monitoring
and clinical toxicology. Ther Drug Monit 2005;27:10–7
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Netilmicin
General
• Class of the drug Aminoglycoside antibiotics
• Synonym(s) –
• Common trade name(s) in Germany Certomycin
• Conversion factors mg/L=2.1smmol/L
mmol/L=0.476smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, suspicion of toxicity, side effects
• Protein binding 0–30% (albumin)
• Elimination half-life 1–3 h
Neonates: 3–8 h (see remarks)
• Volume of distribution 0.3 L/kg
• Metabolism
Main metabolic pathways No metabolism
Active metabolite(s)? None
Inhibitor or inducer of the cytochrome P450 system? No
Other significant pharmacokinetic interactions None
• Elimination of parent drug Renal 100%
• Typical therapeutic range Multiple dosing
Peak concentration: 6–10 mg/L (13–21 mmol/L)
Trough concentration: F1 mg/L (F2.1 mmol/L)
Once-daily dosing
Trough concentration: -0.5 mg/L (-1.1 mmol/L)
• Potentially toxic concentration Multiple dosing
Peak concentration: )12 mg/L ()25 mmol/L)
Trough concentration: )2 mg/L ()4.2 mmol/L)
Once-daily dosing
Trough concentration: )0.5 mg/L ()1.1 mmol/L)
Pre-analytics
• Time to steady-state since beginning of Steady-state is generally achieved after 3 doses for multiple
treatment or change of posology dosing
• Time for blood sampling Peak: 1 h after beginning of infusion
Trough: within 30 min of next dose
Once-daily dosing: trough level only
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
When combined therapy with penicillins and/or
cephalosporins: in vitro inactivation™freeze sample
Remarks • Elimination is strongly dependent on renal function
• Avoid gel tubes if possible, unless having confirmed that no
binding occurs
References • Arzneimittelkompendium Schweiz. Basel: Documed 2005
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie
(16. Auflage). Basel: Documed, 2005
• Taylor WJ, Diers Caviness MH. A textbook for the clinical
application of therapeutic drug monitoring. Irving,
TX: Abbott Laboratories, 1986
• Thomson Micromedex Healthcare series
• Begg EJ, Barclay ML, Duffull SB. A suggested approach to
once-daily aminoglycoside dosing. Br J Clin Pharm
1995;39:605–9
• Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness
of therapeutic drug monitoring committee of the international
association for therapeutic drug monitoring and clinical
toxicology. Ther Drug Monit 2005;27:10–7
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Teicoplanin
General
• Class of the drug Glycopeptide antibiotics
• Synonym(s) –
• Common trade name(s) in Germany Targocid
• Conversion factors Not applicable
Clinical pharmacology
• Indications for TDM Individual dose adaptation, suspicion of toxicity, side effects
• Protein binding 90% (albumin)
• Elimination half-life 70–150 h
Pediatric: 58 h
• Volume of distribution 1.1 L/kg
• Metabolism
Main metabolic pathways No metabolites identified
Active metabolite(s)? None
Inhibitor or inducer of the cytochrome P450 system? No
Other significant pharmacokinetic interactions None
• Elimination of parent drug Renal (80%)
• Typical therapeutic range Trough concentration: -15 mg/L
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of treatment Not relevant
or change of posology
• Time for blood sampling Trough: within 30 min of next dose
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks • Elimination is strongly dependent on renal function
• Avoid gel tubes if possible, unless having confirmed that no
binding occurs
References • Arzneimittelkompendium Schweiz. Basel: Documed 2005
• Thomson Micromedex Healthcare series
• Begg EJ, Barclay ML, Kirkpatrick CJ. The therapeutic
monitoring of antimicrobial agents. Br J Clin Pharm
1999;47:23–30
• Schulz M, Schmoldt A. Therapeutic and toxic blood
concentrations of more than 800 drugs and other
xenobiotics. Pharmazie 2003;58:447–74
• Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness
of therapeutic drug monitoring committee of the
international association for therapeutic drug monitoring
and clinical toxicology. Ther Drug Monit 2005;27:10–7
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Tobramycin
General
• Class of the drug Aminoglycoside antibiotics
• Synonym(s) –
• Common trade name(s) in Germany Gernebcin
• Conversion factors mg/L=2.14smmol/L
mmol/L=0.467smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, suspicion of toxicity, side effects
• Protein binding 0–30% (albumin)
• Elimination half-life 1–3 h
Neonates/infants: 3–8 h (see remarks)
• Volume of distribution 0.3 L/kg
• Metabolism
Main metabolic pathways No metabolism
Active metabolite(s)? None
Inhibitor or inducer of the cytochrome P450 system? No
Other significant pharmacokinetic interactions None
• Elimination of parent drug Renal 100%
• Typical therapeutic range Multiple dosing
Peak concentration: 6–10 mg/L (13–21 mmol/L)
Trough concentration: F1 mg/L (F2.1 mmol/L)
Once-daily dosing
Trough concentration: F0.5 mg/L (F1.1 mmol/L)
• Potentially toxic concentration Multiple dosing
Peak concentration: )12 mg/L ()26 mmol/L)
Trough concentration: )2 mg/L ()4.3 mmol/L)
Once-daily dosing
Trough concentration: )0.5 mg/L ()1.1 mmol/L)
Pre-analytics
• Time to steady-state since beginning of treatment or Steady-state is generally achieved after 3 doses for multiple
change of posology dosing
• Time for blood sampling Peak: 1 h after beginning of infusion
Trough: within 30 min of next dose
Once-daily dosing: trough level only
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
When combined therapy with penicillins and/or
cephalosporins: in vitro inactivation™freeze sample
Remarks • Elimination is strongly dependent on renal function
• Avoid gel tubes if possible, unless having confirmed that no
binding occurs
References • Arzneimittelkompendium Schweiz. Basel: Documed 2005
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie
und Toxikologie, Grundlagen der Arzneimitteltherapie
(16. Auflage). Basel: Documed, 2005
• Taylor WJ, Diers Caviness MH. A textbook for the clinical
application of therapeutic drug monitoring. Irving, TX: Abbott
Laboratories, 1986
• Thomson Micromedex Healthcare series
• Begg EJ, Barclay ML. Aminoglycosides – 50 years on. Br J
Clin Pharm 1995;39:597–603
• Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness
of therapeutic drug monitoring committee of the international
association for therapeutic drug monitoring and clinical
toxicology. Ther Drug Monit 2005;27:10–7
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Vancomycin
General
• Class of the drug Glycopeptide antibiotics
• Synonym(s) –
• Common trade name(s) in Germany Vancomycin ‘‘Lederle’’
• Conversion factors mg/L=0.69smmol/L
mmol/L=1.45smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation, suspicion of toxicity, side effects
• Protein binding 30–55% (albumin)
• Elimination half-life 4–6 h
Neonates: 4–22 h
• Volume of distribution 0.2–1.3 L/kg
• Metabolism
Main metabolic pathways No metabolism
Active metabolite(s)? None
Inhibitor or inducer of the cytochrome P450 system? No
Other significant pharmacokinetic interactions None
• Elimination of parent drug Renal 100%
• Typical therapeutic range Peak concentration: 20–40 mg/L (14–28 mmol/L)
Trough concentration: 5–10 mg/L (3.5–6.9 mmol/L)
• Potentially toxic concentration Peak concentration: lack of evidence for toxicity associated
with peak levels in patients with normal renal function
Trough concentration: )15 mg/L ()10 mmol/L)
Pre-analytics
• Time to steady-state since beginning of Steady-state is generally achieved after 3 doses
treatment or change of posology
• Time for blood sampling Peak: 1 h after beginning of infusion
Trough: within 30 min of next dose
• Type(s) of sample Serum or plasma
• Stability 1 week at 48C
Remarks • Accumulation of vancomycin crystalline degradation
products (CDP) in renally impaired patients may cause falsely
elevated serum vancomycin concentrations with certain
immunoassays
• Incompatibility with heparin, CAVE portacath
• Elimination is strongly dependent on renal function
• Avoid gel tubes if possible, unless having confirmed that no
binding occurs
References • Arzneimittelkompendium Schweiz. Basel: Documed 2005
• Schweizerische Gesellschaft fu¨r Klinische Pharmakologie und
Toxikologie, Grundlagen der Arzneimitteltherapie
(16. Auflage). Basel: Documed, 2005
• Taylor WJ, Diers Caviness MH. A textbook for the clinical
application of therapeutic drug monitoring. Irving,
TX: Abbott Laboratories, 1986
• Thomson Micromedex Healthcare series
• Schulz M, Schmoldt A. Therapeutic and toxic blood
concentrations of more than 800 drugs and other
xenobiotics. Pharmazie 2003;58:447–74
• Touw DJ, Neef C, Thomson AH, Vinks AA. Cost-effectiveness
of therapeutic drug monitoring committee of the
international association for therapeutic drug monitoring and
clinical toxicology. Ther Drug Monit 2005;27:10–7
• Saunders, J. Vancomycin administration and monitoring
reappraisal. Antimicrob Chemother 1995;36:279–82
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Itraconazole
General
• Class of the drug Antimycotics
• Synonym(s) –
• Common trade name(s) in Germany Sempera





• Indications for TDM Individual dose adaptation, verification of compliance
• Protein binding )99% (albumin)
• Elimination half-life 1.0–1.5 days
• Volume of distribution 10.7 L/kg
• Metabolism
Main metabolic pathways Hydroxylation by CYP3A4 to hydroxyitraconazole
(stereoselective biotransformation) and a number of other
metabolites
Active metabolite(s)? Hydroxyitraconazole (should be determined as well)
Inhibitor or inducer of the cytochrome P450 system? Inhibits CYP3A4
Other significant pharmacokinetic interactions Inhibitor of P-gp
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range )0.50 mg/L ()0.71 mmol/L) for itraconazole
)1.0 mg/L ()1.42 mmol/L) for itraconazoleq
hydroxyitraconazole
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of treatment 7–14 days
or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability Several days at 48C
Remarks None
References • Arzneimittel Kompendium Schweiz. Basel: Documed 2005
• Breadmore MC, Thormann, W. Capillary electrophoresis:
evidence for the stereoselective metabolism of itraconazole
in man. Electrophoresis 2003;24:2588–97
• Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E,
Losem C, Sauerbruch T, et al. Breakthrough invasive fungal
infections in neutropenic patients after prophylaxis with
itraconazole. Mycoses 1999;42:443–51
• Heykants J, Vanpeer A, Vandevelde V, Vanrooy P, Meulder-
mans W, Lavrijsen K, et al. The clinical pharmacokinetics of
itraconazole – an overview. Mycoses 1989;32:67–87
• Poirier JM, Cheymol G. A rapid and specific liquid
chromatographic assay for the determination of itraconazole
and hydroxyitraconazole in plasma. Ther Drug Monit
1997;19:247–8
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Voriconazole
General
• Class of the drug Antimycotics
• Synonym(s) –
• Common trade name(s) in Germany Vfend
• Conversion factors mg/L=2.86smmol/L
mmol/L=0.35smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation
• Protein binding 58%
• Elimination half-life Approximately 6 h for 200 mg (non-linear pharmacokinetics)
• Volume of distribution 2–4.6 L/kg
• Metabolism
Main metabolic pathways N-oxidation and hydroxylation by CYP2C19, CYP2C9, CYP3A4
Active metabolite(s)? None
Inhibitor or inducer of the cytochrome P450 system? Inhibits CYP2C19, CYP2C9 and CYP3A4
Other significant pharmacokinetic interactions No
• Elimination of parent drug Mainly hepatic
Renal -2%
• Typical therapeutic range 1–6 mg/L (2.9–17.2 mmol/L)
• Potentially toxic concentration Not known
Pre-analytics
• Time to steady-state since beginning of 5–6 days (approximately 1 day with loading dose)
treatment or change of posology
• Time for blood sampling Before next dose at steady-state
• Type(s) of sample Serum or plasma
• Stability Several days at 48C
Remarks • Genotype status for CYP2C19 and/or co-administration of
drugs that modulate CYP2C19 and CYP3A4 activities could
affect voriconazole drug levels
• The target range for CSF (cerebrospinal fluid) and aqueous
humor is only 50% of the respective value in serum or
plasma, due to missing proteins
References • Arzneimittel Kompendium Schweiz. Basel: Documed 2005
• Hyland R, Jones BC, Smith DA. Identification of the
cytochrome P450 enzymes involved in the N-oxidation
of voriconazole. Drug Metab Dispos 2003;31:540–7
• Johnson LB, Kauffman CA. Voriconazole: a new triazole
antifungal agent. Rev Antiinfect Agents 2003;36:630–7
• Purkins L, Wood N, Greenhalgh K, Eve MD, Oliver SD,
Nichols D. The pharmacokinetics and safety of intravenous
voriconazole – a novel wide-spectrum antifungal agent.
Br J Clin Pharmacol 2003;56:2–9
• Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG,
Nedderman ANR, et al. The disposition of voriconazole in
mouse, rat, rabbit, guinea pig, dog and human. Drug Metab
Dispos 2003;31:731–41
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Mebendazole
General
• Class of the drug Anthelmintics
• Synonym(s) –
• Common trade name(s) in Germany Vermox, Surfont
• Conversion factors mg/L=3.39smmol/L
mmol/L=0.295smg/L
Clinical pharmacology
• Indications for TDM Individual dose adaptation
• Protein binding 90%
• Elimination half-life 2.5–5.5 h
• Volume of distribution Not known
• Metabolism
Main metabolic pathways Formation of amino- and hydroxymetabolites (larger plasma
concentration compared to mebendazole)
Active metabolite(s)? Non-significant activity of major metabolites
Inhibitor or inducer of the cytochrome P450 system? Inducer of hepatic microsomal oxidizing system (enzyme(s) not
known)
Other significant pharmacokinetic interactions Not known
• Elimination of parent drug Mainly hepatic
• Typical therapeutic range )0.074 mg/L ()0.25 mmol/L) for treatment of echinococcosis
• Potentially toxic concentration )1 mg/L ()3.39 mmol/L) should be avoided
Pre-analytics
• Time to steady-state since beginning of treatment or 2–4 days
change of posology
• Time for blood sampling 4 h after last dose
• Type(s) of sample Serum or plasma
• Stability Several days at 48C
Remarks • The large inter- and intra-individual variability is due to the
low bioavailability that is related to the low solubility of
mebendazole; bioavailability is increased with concomitant
intake of a fatty meal
• Cholestasis increases blood levels
• Only serum or plasma samples should be shipped (meben-
dazole is not stable in the collected blood samples)
References • Arzneimittel Kompendium Schweiz. Basel: Documed 2005
• Bresson-Hadni S, Miguet JP, Vuitton DA. Echinococcosis of
the liver. In: Bircher J, Benhamou J-P, McIntyre N, Rizzetto
M, Rode´s J, editors. Oxford textbook of clinical hepatology,
vol. I (2nd ed.). Oxford: Oxford University Press,
1999:1066–76
• Gottstein B, Reichen J. Echinococcosis/hydatidosis. In: Cook
GC, editor. Manson’s tropical diseases. London: Saunders,
1996:1486–508
• Witassek F, Burkhardt B, Eckert J, Bircher J. Chemotherapy
of alveolar echinococcosis. Eur J Clin Pharmacol
1981;20:427–33
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